Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Relationships between DMD mutations and neurodevelopment in dystrophinopathy.

Thangarajh M, Hendriksen J, McDermott MP, Martens W, Hart KA, Griggs RC; Muscle Study Group and TREAT-NMD.

Neurology. 2019 Oct 22;93(17):e1597-e1604. doi: 10.1212/WNL.0000000000008363. Epub 2019 Oct 8.

PMID:
31594858
2.

Ankle bracing practices in ambulatory, corticosteroid-naive boys with Duchenne muscular dystrophy.

Kern V, Wicklund M, Haulman A, McDermott MP, Martens WB, Griggs RC, Kumar A; Muscle Study Group and TREAT-NMD.

Muscle Nerve. 2020 Jan;61(1):52-57. doi: 10.1002/mus.26727. Epub 2019 Oct 16.

PMID:
31588574
3.

Author response: Michael H. Brooke, MB, BCh (1934-2018).

Griggs RC, Mendell JR.

Neurology. 2019 Sep 3;93(10):463. doi: 10.1212/WNL.0000000000008071. No abstract available.

PMID:
31477615
4.

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy.

Ke Q, Zhao ZY, Mendell JR, Baker M, Wiley V, Kwon JM, Alfano LN, Connolly AM, Jay C, Polari H, Ciafaloni E, Qi M, Griggs RC, Gatheridge MA.

World J Pediatr. 2019 Jun;15(3):219-225. doi: 10.1007/s12519-019-00242-6. Epub 2019 Mar 23. Review.

PMID:
30904991
5.

Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.

Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, Stegeman DF, Timmermans J, Trivedi J, Matthews E, Saris CGJ, Schouwenberg BJ, Drost G, van Engelen BGM, van der Wilt GJ.

JAMA. 2018 Dec 11;320(22):2344-2353. doi: 10.1001/jama.2018.18020.

6.

A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.

Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Hirtz D, Lochmuller H, Straub V, Ciafaloni E, Shieh PB, Spinty S, Childs AM, Manzur AY, Morandi L, Butterfield RJ, Horrocks I, Roper H, Flanigan KM, Kuntz NL, Mah JK, Morrison L, Darras BT, von der Hagen M, Schara U, Wilichowski E, Mongini T, McDonald CM, Vita G, Barohn RJ, Finkel RS, Wicklund M, McMillan HJ Jr, Hughes I, Pegoraro E, Bryan Burnette W, Howard JF, Thangarajh M, Campbell C, Griggs RC, Bushby K, Guglieri M.

Trials. 2018 May 10;19(1):291. doi: 10.1186/s13063-018-2645-0. Review.

7.

Long Exercise Test in Periodic Paralysis: A Bayesian Analysis.

Simmons DB, Lanning J, Cleland JC, Puwanant A, Twydell PT, Griggs RC, Tawil R, Logigian EL.

Muscle Nerve. 2019 Jan;59(1):47-54. doi: 10.1002/mus.26157. Epub 2018 Aug 29.

PMID:
29752813
8.

Periodic paralysis.

Fialho D, Griggs RC, Matthews E.

Handb Clin Neurol. 2018;148:505-520. doi: 10.1016/B978-0-444-64076-5.00032-6. Review.

PMID:
29478596
9.

Review of the Diagnosis and Treatment of Periodic Paralysis.

Statland JM, Fontaine B, Hanna MG, Johnson NE, Kissel JT, Sansone VA, Shieh PB, Tawil RN, Trivedi J, Cannon SC, Griggs RC.

Muscle Nerve. 2018 Apr;57(4):522-530. doi: 10.1002/mus.26009. Epub 2017 Nov 29. Review.

10.

Editors' Note.

Karam C, Griggs RC.

Neurology. 2017 Jul 4;89(1):106. doi: 10.1212/WNL.0000000000004072. No abstract available.

PMID:
28674158
11.

Lewis P. Rowland, MD (1925-2017).

Pedley TA, Mayeux R, Griggs RC.

Neurology. 2017 May 23;88(21):1992-1995. doi: 10.1212/WNL.0000000000004027. No abstract available.

PMID:
28533345
12.

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs AM, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC.

Contemp Clin Trials. 2017 Jul;58:34-39. doi: 10.1016/j.cct.2017.04.008. Epub 2017 Apr 24.

14.

Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.

Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM.

Neurology. 2016 Nov 15;87(20):2123-2131. Epub 2016 Aug 26.

15.

China's shift from population control to population quality: Implications for neurology.

Ke Q, Zhang L, He C, Zhao Z, Qi M, Griggs RC, Gatheridge MA.

Neurology. 2016 Aug 23;87(8):e85-8. doi: 10.1212/WNL.0000000000003010. No abstract available.

16.

Rare neurological channelopathies--networks to study patients, pathogenesis and treatment.

Jen JC, Ashizawa T, Griggs RC, Waters MF.

Nat Rev Neurol. 2016 Apr;12(4):195-203. doi: 10.1038/nrneurol.2016.18. Epub 2016 Mar 4. Review.

17.

In vivo impact of presynaptic calcium channel dysfunction on motor axons in episodic ataxia type 2.

Tomlinson SE, Tan SV, Burke D, Labrum RW, Haworth A, Gibbons VS, Sweeney MG, Griggs RC, Kullmann DM, Bostock H, Hanna MG.

Brain. 2016 Feb;139(Pt 2):380-91. doi: 10.1093/brain/awv380.

18.

Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.

Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A, Meola G, Conwit R, Hanna MG, Griggs RC; Muscle Study Group.

Neurology. 2016 Apr 12;86(15):1408-1416. doi: 10.1212/WNL.0000000000002416. Epub 2016 Feb 10.

19.

Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.

Gatheridge MA, Kwon JM, Mendell JM, Scheuerbrandt G, Moat SJ, Eyskens F, Rockman-Greenberg C, Drousiotou A, Griggs RC.

JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537. Review.

PMID:
26594870
20.

WriteClick nonresponders: Waiting, waffling, or weasling?

Pieper KM, Griggs RC.

Neurology. 2015 Sep 15;85(11):924. doi: 10.1212/WNL.0000000000001936. No abstract available.

PMID:
26370188
21.

Advances in Muscular Dystrophies.

Kang PB, Griggs RC.

JAMA Neurol. 2015 Jul;72(7):741-2. doi: 10.1001/jamaneurol.2014.4621. Review. No abstract available.

PMID:
25985443
22.

Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol.

Stunnenberg BC, Woertman W, Raaphorst J, Statland JM, Griggs RC, Timmermans J, Saris CG, Schouwenberg BJ, Groenewoud HM, Stegeman DF, van Engelen BG, Drost G, van der Wilt GJ.

BMC Neurol. 2015 Mar 25;15:43. doi: 10.1186/s12883-015-0294-4.

23.

Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Kang PB, Morrison L, Iannaccone ST, Graham RJ, Bönnemann CG, Rutkowski A, Hornyak J, Wang CH, North K, Oskoui M, Getchius TS, Cox JA, Hagen EE, Gronseth G, Griggs RC; Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Neurology. 2015 Mar 31;84(13):1369-78. doi: 10.1212/WNL.0000000000001416.

24.

Cystic fibrosis newborn screening: a model for neuromuscular disease screening?

Scully MA, Farrell PM, Ciafaloni E, Griggs RC, Kwon JM.

Ann Neurol. 2015 Feb;77(2):189-97. doi: 10.1002/ana.24316. Epub 2014 Dec 13. Review.

PMID:
25425541
25.

Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, Wicklund M, Barohn RJ, Ensrud E, Griggs RC, Gronseth G, Amato AA; Guideline Development Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Neurology. 2014 Oct 14;83(16):1453-63. doi: 10.1212/WNL.0000000000000892.

26.

State neurologic societies and the AAN: Strengthening neurology for the future.

Narayanaswami P, Showers D, Levi B, Showers M, Jones EC, Busis NA, Comella CL, Pulst SM, Hosey JP, Griggs RC.

Neurol Clin Pract. 2014 Jun;4(3):247-255.

27.

Lessons from the dust: are some members more equal than others?

Griggs RC, Rydell CM.

Neurology. 2014 Jul 22;83(4):302-3. doi: 10.1212/WNL.0000000000000631. Epub 2014 Jun 18. No abstract available.

PMID:
24944255
28.

Global opportunities and challenges for clinical neuroscience.

Birbeck GL, Hanna MG, Griggs RC.

JAMA. 2014 Apr 23-30;311(16):1609-10. doi: 10.1001/jama.2014.2744. No abstract available.

PMID:
24756506
29.

Author response.

Freeman WD, Vatz KA, Griggs RC, Pedley T.

Neurology. 2014 Mar 4;82(9):818. No abstract available.

PMID:
24734286
30.

Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP) mutations in the actin-binding domain cause disruption of skeletal muscle actin filaments in myofibrillar myopathy.

Lin X, Ruiz J, Bajraktari I, Ohman R, Banerjee S, Gribble K, Kaufman JD, Wingfield PT, Griggs RC, Fischbeck KH, Mankodi A.

J Biol Chem. 2014 May 9;289(19):13615-26. doi: 10.1074/jbc.M114.550418. Epub 2014 Mar 25.

31.

Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.

Graves TD, Cha YH, Hahn AF, Barohn R, Salajegheh MK, Griggs RC, Bundy BN, Jen JC, Baloh RW, Hanna MG; CINCH Investigators.

Brain. 2014 Apr;137(Pt 4):1009-18. doi: 10.1093/brain/awu012. Epub 2014 Feb 26.

32.

Nondystrophic myotonia: challenges and future directions.

Trivedi JR, Cannon SC, Griggs RC.

Exp Neurol. 2014 Mar;253:28-30. doi: 10.1016/j.expneurol.2013.12.005. Epub 2013 Dec 18.

33.

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Peay HL, Scully MA, Cwik VA, Ciafaloni E, Griggs RC.

Neurology. 2013 Nov 12;81(20):1802. doi: 10.1212/01.wnl.0000435756.50142.45. No abstract available.

PMID:
24218315
34.

Rare disease centers for periodic paralysis: China versus the United States and United Kingdom.

Ke Q, Qi M, Wu W, Luo B, Hanna M, Herr B, Griggs RC; Consortium for Investigation of Neurological Channelopathies (CINCH).

Muscle Nerve. 2014 Feb;49(2):171-4. doi: 10.1002/mus.23970.

PMID:
23893386
35.

The Workforce Task Force report: clinical implications for neurology.

Freeman WD, Vatz KA, Griggs RC, Pedley T.

Neurology. 2013 Jul 30;81(5):479-86. doi: 10.1212/WNL.0b013e31829d8783. Epub 2013 Jun 19. Review.

36.

Non-dystrophic myotonia: prospective study of objective and patient reported outcomes.

Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ; CINCH Consortium.

Brain. 2013 Jul;136(Pt 7):2189-200. doi: 10.1093/brain/awt133. Epub 2013 Jun 13.

37.

Corticosteroids in Duchenne muscular dystrophy: major variations in practice.

Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, McColl E, Tawil R, Pandya S, McDermott MP, Bushby K.

Muscle Nerve. 2013 Jul;48(1):27-31. doi: 10.1002/mus.23831. Epub 2013 Apr 25.

PMID:
23483575
38.

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Scully MA, Cwik VA, Marshall BC, Ciafaloni E, Wolff JM, Getchius TS, Griggs RC.

Neurology. 2013 Feb 5;80(6):583-9. doi: 10.1212/WNL.0b013e318282334e. Review.

39.

Unintended effects of orphan product designation for rare neurological diseases.

Murphy SM, Puwanant A, Griggs RC; Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network.

Ann Neurol. 2012 Oct;72(4):481-90. doi: 10.1002/ana.23672. Review.

40.

Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG; Consortium for Clinical Investigation of Neurologic Channelopathies.

JAMA. 2012 Oct 3;308(13):1357-65. doi: 10.1001/jama.2012.12607.

41.

Emerging subspecialties in neurology: fellowship in experimental therapeutics of neurologic disease.

Statland JM, Griggs RC, Augustine EF.

Neurology. 2012 Sep 25;79(13):e106-8. No abstract available.

42.

A quantitative measure of handgrip myotonia in non-dystrophic myotonia.

Statland JM, Bundy BN, Wang Y, Trivedi JR, Raja Rayan D, Herbelin L, Donlan M, McLin R, Eichinger KJ, Findlater K, Dewar L, Pandya S, Martens WB, Venance SL, Matthews E, Amato AA, Hanna MG, Griggs RC, Barohn RJ; CINCH Consortium.

Muscle Nerve. 2012 Oct;46(4):482-9. doi: 10.1002/mus.23402.

43.

American Academy of Neurology policy on pharmaceutical and device industry support.

Hutchins JC, Rydell CM, Griggs RC, Sagsveen M, Bernat JL; American Academy of Neurology Pharmaceutical and Device Industry Conflict of Interest Task Force.

Neurology. 2012 Mar 6;78(10):750-4. doi: 10.1212/WNL.0b013e318248e4ff.

PMID:
22391605
44.

Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.

Platt D, Griggs RC.

Arch Neurol. 2012 Apr;69(4):527-9. doi: 10.1001/archneurol.2011.2723. Epub 2011 Dec 12.

45.

Global imperatives and challenges facing the practice of neurology.

Griggs RC, Fontaine B, Sobue G.

Neurol Clin Pract. 2011 Dec;1(1):49-54. doi: 10.1212/CPJ.0b013e31823b4e83.

46.

Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype.

Matthews E, Portaro S, Ke Q, Sud R, Haworth A, Davis MB, Griggs RC, Hanna MG.

Neurology. 2011 Nov 29;77(22):1960-4. doi: 10.1212/WNL.0b013e31823a0cb6. Epub 2011 Nov 16.

47.

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy: predicting the severity of Duchenne muscular dystrophy: implications for treatment.

Kyriakides T, Pegoraro E, Hoffman EP, Piva L, Cagnin S, Lanfranchi G, Griggs RC, Nelson SF.

Neurology. 2011 Nov 15;77(20):1858; author reply 1858-9. doi: 10.1212/WNL.0b013e318239b9ae. No abstract available.

PMID:
22084278
48.

Neurology (1997-2006): "A man's reach must exceed his grasp"--from Andrea del Sarto, Robert Browning.

Griggs RC.

Neurology. 2011 Sep 6;77(10):928-9. doi: 10.1212/WNL.0b013e31822cfc1e. No abstract available.

PMID:
21893667
49.

Treating the chief complaint: hand rejuvenation for Hirayama disease.

Puwanant A, Evangelisti SM, Griggs RC.

Neurology. 2011 Jul 12;77(2):190-1. doi: 10.1212/WNL.0b013e3182242da7. Epub 2011 Jun 29. No abstract available.

50.

Overview of the muscular dystrophies.

Amato AA, Griggs RC.

Handb Clin Neurol. 2011;101:1-9. doi: 10.1016/B978-0-08-045031-5.00001-3. Review.

PMID:
21496621

Supplemental Content

Loading ...
Support Center